Eolo Pharma is focused on developing innovative pharmacological treatments aimed at addressing obesity and its related comorbidities. The company boasts a diverse pipeline featuring a library of 60 novel chemical entities (NCEs), with MVD1 being the lead compound specifically targeting obesity. This compound is designed to tackle not only obesity itself but also associated conditions such as Type II diabetes, non-alcoholic steatohepatitis (NASH), and hypertension. Eolo Pharma's approach emphasizes the creation of personalized therapeutic solutions that enhance the overall well-being and vitality of patients, reflecting their commitment to improving health outcomes.

In addition to their lead compound, Eolo Pharma is engaged in advanced research that explores the mechanisms underlying various health conditions. Their scientific endeavors include the investigation of small molecules that target inflammatory pathways, such as NF-κB inhibition, which has implications for diseases like ALS and obesity-related inflammation. The company is dedicated to bridging the gap between scientific research and practical healthcare solutions, as evidenced by their peer-reviewed publications that contribute to the understanding of obesity, inflammation, and metabolic disorders. Through these efforts, Eolo Pharma aims to unlock new possibilities in therapeutic interventions and enhance the quality of life for individuals affected by these conditions.

United States

EOLO PHARMA is a pharmaceutical company that focuses on drug discovery and developing novel molecules for the treatment of obesity.

Eolo Pharma

Company Details